MORE►
Actium Group
Signify Bio co-founders, from left: CEO R.A. Session II and Chief Scientific Officer Daniel Siegwart, Ph.D., of UT Southwestern. {Photos: Taysha Gene Therapies/UTSW]
Dallas’ Signify Bio Launches With Oversubscribed $15M Financing, Partnership With UT Southwestern
by Lance Murray | Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
by Quincy Preston |
Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
MORE►
